Evidence map›Paper›PMID 11823424›Full record

ArticleThe EMBO journal2002

A "three-pronged" binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome.

Peter M Hwang, Chengjun Li, Massimo Morra, Jennifer Lillywhite, D Ranjith Muhandiram, Frank Gertler, Cox Terhorst, Lewis E Kay, Tony Pawson, Julie D Forman-Kay and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 86 citations in OpenAlex.

  1. Review
  2. SH2 Domains: Folding, Binding and Therapeutical Approaches.International journal of molecular sciences · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. SH2 Domain Binding: Diverse FLVRs of Partnership.Frontiers in endocrinology · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Peter M HwangDepartment of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
Chengjun Li
Massimo Morra
Jennifer Lillywhite
D Ranjith Muhandiram
Frank Gertler
Cox Terhorst
Lewis E Kay
Tony Pawson
Julie D Forman-Kay
Shun-Cheng Li
University of Toronto · CAWestern University · CAHarvard University · USMassachusetts Institute of Technology · USMount Sinai Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SH2 domain protein SAP/SH2D1A, encoded by the X-linked lymphoproliferative (XLP) syndrome gene, associates with the hematopoietic cell surface receptor SLAM in a phosphorylation-independent manner. By screening a repertoire of synthetic peptides, the specificity of SAP/SH2D1A has been mapped and a consensus sequence motif for binding identified, T/S-x-x-x-x-V/I, where x represents any amino acid. Remarkably, this motif contains neither a Tyr nor a pTyr residue, a hallmark of conventional SH2 domain-ligand interactions. The structures of the protein, determined by NMR, in complex with two distinct peptides provide direct evidence in support of a "three-pronged" binding mechanism for the SAP/SH2D1A SH2 domain in contrast to the "two-pronged" binding for conventional SH2 domains. Differences in the structures of the two complexes suggest considerable flexibility in the SH2 domain, as further confirmed and characterized by hydrogen exchange studies. The structures also explain binding defects observed in disease-causing SAP/SH2D1A mutants and suggest that phosphorylation-independent interactions mediated by SAP/SH2D1A likely play an important role in the pathogenesis of XLP.

Indexed as

Intracellular Signaling Peptides and ProteinsAntigens, CDCarrier ProteinsConsensus SequenceGlycoproteinsHumansImmunoglobulinsLymphoproliferative DisordersMutationPeptide MappingPhosphorylationProtein BindingReceptors, Cell SurfaceSignaling Lymphocytic Activation Molecule Associated ProteinSignaling Lymphocytic Activation Molecule Family Member 1src Homology DomainsAntigens, CDCarrier ProteinsGlycoproteinsImmunoglobulinsIntracellular Signaling Peptides and ProteinsReceptors, Cell SurfaceSH2D1A protein, humanSignaling Lymphocytic Activation Molecule Associated ProteinSignaling Lymphocytic Activation Molecule Family Member 1Tyrosine

Identifiers

PMID11823424
PMCPMC125837
OpenAlexW2156876193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.